Clinical trials: Metastatic Cancers
Metastatic Colorectal Cancer (mCRC)
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
This trial is conducted in patients with the recurrent lesion(s) post-surgery or the untreated mCRC. After stratification with respect to ECOG PS score, chemo regimen, primary tumor location and KRAS and BRAF genotype (complete…
- Trial name
- NCT03511963
- Testing
- HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection
- Where
- China
- Volunteers
- 677 people
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Colorectal Cancer
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with…
- Trial name
- NCT00856375
- Testing
- NKTR-102, irinotecan
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 83 people
- Sponsor
- Nektar Therapeutics
Metastatic Pancreatic Cancer
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
- Trial name
- NCT02570711
- Testing
- ACP-196, Nab-paclitaxel, Gemcitabine
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Acerta Pharma BV
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal…
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Trial name
- NCT03412799
- Testing
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Where
- 7 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Panbela Therapeutics, Inc.
Squamous Non-small Cell Lung Cancer
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
This study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared…
- Trial name
- NCT07360132
- Testing
- Carboplatin Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Non-Small-Cell Lung Carcinoma
Phase II Iressa Versus Vinorelbine (INVITE)
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day…
- Trial name
- NCT00256711
- Testing
- Gefitinib, Vinorelbine
- Where
- 55 sites in Australia, Brazil and 8 more
- Volunteers
- 192 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC).
- Trial name
- NCT00087711
- Testing
- pemetrexed, gemcitabine, cisplatin
- Where
- 134 sites in United States, Argentina and 25 more
- Volunteers
- 1,713 people
- Sponsor
- Eli Lilly and Company
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
Prostate Cancer
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
This is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or metastatic disease and who have had prior anti-androgen…
- Trial name
- NCT00278993
- Testing
- E7389
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Eisai Inc.
Prostatic Neoplasms, Castration-Resistant
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated…
- Trial name
- BELFIGO (NCT03563014)
- Testing
- Radium-223 (Xofigo, Bay88-8223)
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Bayer
Metastatic Non-small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
- Trial name
- TROPION-Lung15 (NCT06417814)
- Testing
- Dato-DXd, Osimertinib, Pemetrexed
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX301…
- Trial name
- NCT05102214
- Testing
- HLX301
- Where
- 5 sites in Australia
- Volunteers
- 150 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Castration-resistant Prostate Cancer
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer…
- Trial name
- EXPLORE (NCT04268628)
- Testing
- Serum and plasma samples analysis
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Locally Recurrent and Metastatic Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel…
- Trial name
- NCT00322400
- Testing
- Docetaxel, Paclitaxel, AMG 706
- Volunteers
- 46 people
- Sponsor
- Amgen
Solid Tumor, Lymphoma
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when…
- Trial name
- NCT03249792
- Testing
- MK-2118 (IT), MK-2118 (SC), Pembrolizumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer
Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or…
- Trial name
- NCT06873763
- Testing
- Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
- Where
- 5 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- STCube, Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.